Innate Pharma (LTS:0EVI) OCF Margin %: -125.00% (As of Dec. 2025)

What is Innate Pharma OCF Margin %?

Innate Pharma LTS:0EVI +3.18% 41 OCF Margin % is -125.00% as of Dec. 2025. GuruFocus rates LTS:0EVI with a GF Score™ of 41/100 and a GF Value™ of €0.14 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 959 Biotechnology companies, Innate Pharma ranks worse than 81.33% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Innate Pharma's Cash Flow from Operations for the six months ended in Dec. 2025 was €-1.40 Mil. Innate Pharma's Revenue for the six months ended in Dec. 2025 was €1.12 Mil. Therefore, Innate Pharma's OCF Margin % for the quarter that ended in Dec. 2025 was -125.00%.

As of today, Innate Pharma's current OCF Yield % is -20.64%.

The historical rank and industry rank for Innate Pharma's OCF Margin % or its related term are showing as below:

LTS:0EVI' s OCF Margin % Range Over the Past 10 Years
Min: -1168.25 Med: -78.91 Max: 50.9
Current: -1168.25

During the past 13 years, the highest OCF Margin % of Innate Pharma was 50.90%. The lowest was -1168.25%. And the median was -78.91%.

LTS:0EVI's OCF Margin % is ranked worse than
81.33% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs LTS:0EVI: -1168.25

Innate Pharma OCF Margin % Related Terms

Innate Pharma OCF Margin % Historical Data

* Premium members only.

The historical data trend for Innate Pharma's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innate Pharma OCF Margin % Chart

Innate Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

-482.72

-38.63

-101.65

-54.64

-1,168.25

Innate Pharma Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
OCF Margin %	Get a 7-Day Free Trial															-249.38	36.61	-229.48	-1,864.99	-125.00

LTS:0EVI vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Innate Pharma's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Innate Pharma's OCF Margin % falls into.

Save Embed

41GF Score

Innate Pharma SA LTS:0EVI

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Innate Pharma OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Innate Pharma's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-32.559	/	2.787
	=	-1,168.25 %

Innate Pharma's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	-1.395	/	1.116
	=	-125.00 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of -125.00% mean?

Innate Pharma (LTS:0EVI) has a OCF Margin % of -125.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Innate Pharma and its competitors. According to the industry distribution chart, Innate Pharma ranks #780 out of 959 companies in the Biotechnology industry, placing it in the top 81.3%.

Is Innate Pharma's OCF Margin % too high?

Innate Pharma's current OCF Margin % is -125.00%. Based on the distribution chart, Innate Pharma ranks #780 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Innate Pharma's OCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Innate Pharma ranks #780 out of 959 companies for OCF Margin %. This places Innate Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Innate Pharma and its competitors. Innate Pharma's current OCF Margin % is -125.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Innate Pharma stock overvalued right now?

Based on GuruFocus' analysis, Innate Pharma (LTS:0EVI) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.14, compared to a current price of €1.66 — trading 1082.1% above its estimated fair value. The current OCF Margin % is -125.00%. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Innate Pharma (LTS:0EVI), the current OCF Margin % is -125.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innate Pharma (LTS:0EVI) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of €1.66 is trading 1082.1% above its estimated GF Value™ of €0.14. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for LTS:0EVI:

OCF Margin %: -125.00%
GF Value™: €0.14 vs. price of €1.66 (1082.1% above fair value)
GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the LTS:0EVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies XPAR:ABNX XPAR:OSE XPAR:ALVIO XPAR:ADOC XPAR:ALSEN XPAR:TNG XPAR:ALGAE XPAR:ALTHX XPAR:MAAT XPAR:ALCOX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges IPHYF:USA IPHA:USA IPH:France IDD:Germany

Address 117, Avenue de Luminy, Marseille, FRA, 13009

Website https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

41GF Score

Get the complete analysis for LTS:0EVI

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.66

Price

€0.14

GF Value

View LTS:0EVI Analysis

See OCF Margin % data for all stocks →